OptimizeRx Corp (OPRX) reports a 14% increase in fourth-quarter revenue and significant gross margin improvement, while transitioning to a subscription-based model for enhanced predictability.

The company's acquisition of Medicx in October 2023 for $95 million was aimed at creating a unified direct-to-consumer (DTC) and healthcare provider (HCP) marketing platform. However, growth in the ...

The company's acquisition of Medicx in October 2023 for $95 million was aimed at creating a unified direct-to-consumer (DTC) and healthcare provider (HCP) marketing platform. However, growth in ...

Our customers remain deeply embedded within our ecosystem of offerings, and it remains our goal to help them stay present throughout the patient care journey across our integrated HCP and DTC ...

Q4 2024 Earnings Call Transcript March 12, 2025 OptimizeRx Corporation beats earnings expectations. Reported EPS is $0.3, ...

Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of ...

Our customers remain deeply embedded within our ecosystem of offerings, and it remains our goal to help them stay present throughout the patient care journey across our integrated HCP and DTC business ...

ZoomRx has dug into its data to see what messages resonate with healthcare professionals (HCPs) at different stages | ZoomRx ...

The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company’s definitive proxy statement which will be filed with the Securities and Exchange ...

By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment ...